RxDoctor Payments Data

Samantha Gillenwater, MD

Pulmonary Disease · Weston, FLNPI 1790131613

Payments from drug & device makers

$95,812in general payments, 2019–2025

Across 292 payments — averaging $328.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$53K
  • Janssen Research & Development, LLC$35K
  • AstraZeneca$2K
  • United Therapeutics Corporation$1K
  • GSK$1K
  • Boehringer Ingelheim$588
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$2000%
  • Speaking & faculty fees$42,00070%
  • Travel & lodging$6,12510%
  • Food & beverage$12,01720%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,812 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$109,073
Medicare patients
443
Services billed
1,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan94$1,163,156
UptraviSelexipag41$1,011,233
AdempasRiociguat68$922,223
Orenitram ErTreprostinil Diolamine28$202,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$77,915
TezspireTezepelumab-Ekko14$63,600
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$25,950
Ambrisentan14$13,832
Tadalafil47$13,428
EliquisApixaban15$10,478
SymbicortBudesonide/Formoterol Fumarate31$7,760
Albuterol Sulfate HfaAlbuterol Sulfate100$2,377
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,248
Sildenafil Citrate38$1,069
Fluticasone Propionate68$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$52,516$2,174,389135 claims
BayerAdempas$454$922,22368 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,383$103,864153 claims
AstraZenecaTezspire, Symbicort$1,506$71,35945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →